How effective is Brigatinib/Brigatinib?

Brigatinib is a kinase inhibitor indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer in a U.S. Food and Drug Administration (FDA)-approved test.

Brigatinib/Brigatinibhas been shown to be effective in the treatment of ALK-positive non-small cell lung cancer in two major studies. The first study involved 222 patients whose disease progressed despite prior treatment with crizotinib. Brigatinib/Brigatinib was not compared to any other treatment or to placebo (dummy treatment). Response to treatment is assessed using body scans and standardized criteria for solid tumors, with a complete response being considered when a patient has no remaining signs of cancer. About 56%of patients who received mgAlunbrig daily and increased it to 180mg 7 days later showed a complete or partial response to the drug. Responses lasted an average of about 14 months. The second study involved 275 patients who had not previously received an ALK inhibitor. In this study, patients treated with Alunbrig took an average of 24 months to progress, compared with 11 months for those treated with crizotinib. Generic drugs of this drug are produced in Laos and Bangladesh, and they are all officially marketed generic drugs. The retail price of Laos United Pharmaceuticals90mg30 capsules900RMB, the retail price of Laos and ASEAN pharmaceuticals90mg21 tablets1900around, the retail price of Bangladesh Beacon Pharmaceutical90mg30 tablets3200around, Bangladesh Yaopin International Pharmaceutical2200around yuan. If you want to get more high-quality information, you can contact YaoDe,Yaidewill do its best to learn more about high-quality overseas drugs for you.